// App-Quantinova.ai

THU0204 : A SUBGROUP ANALYSIS OF LOW DISEASE ACTIVITY AND REMISSION FROM PHASE 3 STUDY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARDS

Researchers

Presenter

  • J. E. Gottenberg

Principal Investigators

  • M. H. Buch

  • R. Caporali

  • G. C. Wright

  • T. Takeuchi

  • K. Kalunian

  • A. Pechonkina

  • Y. Guo

  • S. Rao

  • Y. Tan

  • R. Besuyen

  • M. C. Genovese

Medical Centers

  • Strasbourg University, Strasbourg, France

  • Univ of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom

  • Univ of Milan, Rheumatology Division, Hospital G. Pini-CTO, Milan, Italy

  • Grace C Wright MD PC, New York, NY, United States of America

  • Keio Univ. School of Medicine, Tokyo, Japan

  • University of California San Diego”, Division of Rheumatology, Allergy and Immunology, La Jolla, United States of America

  • Gilead Sciences, Inc., Foster City, CA, United States.

  • Galapagos, Nv, Leiden, The Netherlands

  • Stanford University, Materials Science & Engineering, Stanford, United States of America

Locations

  • France

  • United Kingdom

  • Italy

  • United States

  • Japan

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02873936

Sponsors

  • BMS Infotech

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved